JGC
AXSM icon

J. Goldman & Co’s Axsome Therapeutics AXSM Stock Holding History

J. Goldman & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63M Buy
+23,014
New +$4.99M 0.15% 186
2025
Q4 		– Sell
-8,401
Closed -$1.17M – 572
2025
Q3 		$1.02M Sell
8,401
-31,254
-79% -$3.52M 0.03% 328
2025
Q2 		$4.14M Buy
39,655
+37,359
+1,627% +$3.96M 0.1% 217
2025
Q1 		$268K Sell
2,296
-38,027
-94% -$4.33M 0.01% 425
2024
Q4 		$3.41M Buy
40,323
+32,044
+387% +$2.95M 0.09% 226
2024
Q3 		$744K Sell
8,279
-57
-0.7% -$4.97K 0.02% 317
2024
Q2 		$671K Sell
8,336
-560
-6% -$41.5K 0.02% 342
2024
Q1 		$710K Buy
8,896
+3,341
+60% +$280K 0.02% 298
2023
Q4 		$442K Sell
5,555
-48,256
-90% -$3.23M 0.02% 272
2023
Q3 		$3.76M Buy
53,811
+37,865
+237% +$2.83M 0.13% 153
2023
Q2 		$1.15M Sell
15,946
-46,405
-74% -$3.42M 0.04% 243
2023
Q1 		$3.85M Buy
62,351
+59,652
+2,210% +$3.92M 0.16% 165
2022
Q4 		$208K Buy
+2,699
New +$161K 0.01% 312
2020
Q1 		– Sell
-3,753
Closed -$388K – 249
2019
Q4 		$388K Sell
3,753
-7,624
-67% -$308K 0.03% 227
2019
Q3 		$230K Buy
11,377
+1,699
+18% +$43.7K 0.02% 259
2019
Q2 		$249K Sell
9,678
-37,295
-79% -$748K 0.02% 244
2019
Q1 		$668K Buy
+46,973
New +$436K 0.04% 220

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Goldman & Co's AXSM Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 23,014 shares worth $5.63M. The stake represents 0.15% of the portfolio and ranks #186 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in AXSM as recently as Q3 2025.

J. Goldman & Co first reported a position in AXSM in Q1 2019 and has held it in 17 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • J. Goldman & Co held 23,014 shares of Axsome Therapeutics worth $5.63M as of Q2 2026.
  • Axsome Therapeutics was a new J. Goldman & Co position in Q2 2026.
  • Axsome Therapeutics made up 0.15% of J. Goldman & Co's portfolio in Q2 2026, its #186 holding.
  • J. Goldman & Co first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.